Shionogi & Co., Ltd. (SGIOF) は上場企業です ヘルスケア セクターの Drug Manufacturers - Specialty & Generic 業界で事業展開. 本社所在地は Osaka, 日本. 現CEOは Isao Teshirogi.
SGIOF を有する IPO日 2018-02-28, 4,955 名の正社員, に上場 Other OTC, 時価総額 $18.59B.
Shionogi & Co., Ltd. is a Japanese pharmaceutical company founded in 1878 and headquartered in Osaka that engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices. The company's marketed products include Fetroja for multidrug-resistant gram-negative bacterial infections, Xofluza for influenza, and Tivicay for HIV treatment. Shionogi maintains a substantial pipeline of drug candidates across multiple therapeutic areas including infectious diseases, oncology, central nervous system disorders, and rare diseases, with notable programs in obesity, depression, neuropathic pain, and COVID-19 treatments. The company also collaborates with leading academic institutions including Nagasaki University and the National Institute of Infectious Diseases on antimalarial drug development initiatives.
